Review



alphalisa hiblock buffer  (Revvity)


Bioz Verified Symbol Revvity is a verified supplier
Bioz Manufacturer Symbol Revvity manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91

    Structured Review

    Revvity alphalisa hiblock buffer
    ASO-001933 is a highly potent and selective ASO targeting MAPT on human neurons (A) Schematic diagram of ASO treatment schedule in hESCs for (B)–(F). (B) Dose-dependent reduction of MAPT expression at RNA and protein level upon ASO-001933 or BIIB080 treatment. hESC-derived neurons were treated with ASO at indicated concentrations. RNA and protein levels were assessed by qRT-PCR and <t>AlphaLISA</t> respectively. Absolute IC 50 values are reported in the figure (n = 3 /treatment, mean +/- SEM). (C) Quantification of 3R and 4R Tau mRNA by qPCR after ASO treatment at 1 μM (n = 3 /treatment, mean +/- SEM). (D and E) Representative images of RNAscope ISH and ICC using probes against MAPT CDS, MAPT 3′ UTR (D) and antibody against Tau (Tau HT7) (E). (F) Volcano plot illustrating differentially regulated proteins from proteomics analysis between ASO-001933-treated cells versus NT ASO-treated neurons (n = 3). MAPT is the only significantly regulated protein (Log2 FC = −2.94, adjusted Log10 p value = −4.54). (G) Evaluation of off-target effects of ASO-001933 in hiPSC-derived neurons. Volcano plot showing differentially expressed genes (Log2FC > 1 or Log2FC< −1 and −Log10 adjusted p >20) from RNA-seq analysis after 72 h of treatment (n = 3).
    Alphalisa Hiblock Buffer, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alphalisa+buffer/AlphaLISA+HiBlock+Buffer%2C+10X/pmc09424863-307-6-9
    Average 91 stars, based on 6 article reviews
    alphalisa hiblock buffer - by Bioz Stars, 2026-11
    91/100 stars

    Images

    1) Product Images from "Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies"

    Article Title: Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies

    Journal: Molecular Therapy. Nucleic Acids

    doi: 10.1016/j.omtn.2022.07.027

    ASO-001933 is a highly potent and selective ASO targeting MAPT on human neurons (A) Schematic diagram of ASO treatment schedule in hESCs for (B)–(F). (B) Dose-dependent reduction of MAPT expression at RNA and protein level upon ASO-001933 or BIIB080 treatment. hESC-derived neurons were treated with ASO at indicated concentrations. RNA and protein levels were assessed by qRT-PCR and AlphaLISA respectively. Absolute IC 50 values are reported in the figure (n = 3 /treatment, mean +/- SEM). (C) Quantification of 3R and 4R Tau mRNA by qPCR after ASO treatment at 1 μM (n = 3 /treatment, mean +/- SEM). (D and E) Representative images of RNAscope ISH and ICC using probes against MAPT CDS, MAPT 3′ UTR (D) and antibody against Tau (Tau HT7) (E). (F) Volcano plot illustrating differentially regulated proteins from proteomics analysis between ASO-001933-treated cells versus NT ASO-treated neurons (n = 3). MAPT is the only significantly regulated protein (Log2 FC = −2.94, adjusted Log10 p value = −4.54). (G) Evaluation of off-target effects of ASO-001933 in hiPSC-derived neurons. Volcano plot showing differentially expressed genes (Log2FC > 1 or Log2FC< −1 and −Log10 adjusted p >20) from RNA-seq analysis after 72 h of treatment (n = 3).
    Figure Legend Snippet: ASO-001933 is a highly potent and selective ASO targeting MAPT on human neurons (A) Schematic diagram of ASO treatment schedule in hESCs for (B)–(F). (B) Dose-dependent reduction of MAPT expression at RNA and protein level upon ASO-001933 or BIIB080 treatment. hESC-derived neurons were treated with ASO at indicated concentrations. RNA and protein levels were assessed by qRT-PCR and AlphaLISA respectively. Absolute IC 50 values are reported in the figure (n = 3 /treatment, mean +/- SEM). (C) Quantification of 3R and 4R Tau mRNA by qPCR after ASO treatment at 1 μM (n = 3 /treatment, mean +/- SEM). (D and E) Representative images of RNAscope ISH and ICC using probes against MAPT CDS, MAPT 3′ UTR (D) and antibody against Tau (Tau HT7) (E). (F) Volcano plot illustrating differentially regulated proteins from proteomics analysis between ASO-001933-treated cells versus NT ASO-treated neurons (n = 3). MAPT is the only significantly regulated protein (Log2 FC = −2.94, adjusted Log10 p value = −4.54). (G) Evaluation of off-target effects of ASO-001933 in hiPSC-derived neurons. Volcano plot showing differentially expressed genes (Log2FC > 1 or Log2FC< −1 and −Log10 adjusted p >20) from RNA-seq analysis after 72 h of treatment (n = 3).

    Techniques Used: Expressing, Derivative Assay, Quantitative RT-PCR, RNA Sequencing Assay

    Related Articles

    Incubation:

    Article Title: β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer’s Disease
    Article Snippet: An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pKa and thereby dramatically change the pharmacological profile of this class of BACE1 inhibitors.. The CF3 substituted oxazine 89, a potent and highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF Aβ40 & 42 in rats at oral doses as low as 1 mg/kg.. The effect was long lasting, showing a significant reduction of Aβ40 & 42 even after 24 h. In contrast to 89, compound 1b lacking the CF3 group was virtually inactive in vivo.

    Article Title: Tau Protein Modulates an Epigenetic Mechanism of Cellular Senescence
    Article Snippet: Cell lysates were treated with benzonase (707463, Novagen) for 15 min at 37°C, centrifuged at 20’000 g for 10 min at 4°C and supernatants were collected as cell extracts. .. These latter were diluted in HiBlock buffer (10205589, PerkinElmer) and incubated overnight at 4°C with 0.5 μg of primary antibodies against SUZ12 (3737, Cell Signaling Technology), or EZH2 (5246, Cell Signaling Technology). .. Protein G-Sepharose beads (101241, Invitrogen) were added for 1 h at room temperature (RT) and the beads were washed three times in PBS with 0.1% Tween-20.

    Protein Concentration:

    Article Title: Decreased striatal adenosine A 2A -dopamine D 2 receptor heteromerization in schizophrenia
    Article Snippet: PVDF membranes were washed with PBS-T three times (5 min each) before incubation with either a horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1/30,000; Pierce Biotechnology, Rockford, IL, USA), HRP-conjugated rabbit anti-goat IgG (1/10,000; Pierce Biotechnology) or HRP-conjugated rabbit anti-guinea pig IgG (1/3,000; Pierce Biotechnology) in blocking solution at 20 °C during 2 h. After washing the PVDF membranes with PBS-T three times (5 min each), the immunoreactive bands were developed using a chemiluminescent detection kit (Thermo Fisher Scientific, Waltham, MA, USA) and were detected with an Amersham Imager 600 (GE Healthcare Europe GmbH, Barcelona, Spain). .. Mouse striatal and human caudate membranes were homogenized in AlphaLISA buffer (AlphaLISA HiBlock Buffer, PerkinElmer, Waltham, MA, EEUU) and protein concentration determined. .. Thus, 5 μg of protein/well was placed in white 384 well-plates (384 Well Small VolumeTM HiBase Microplates, Greiner Bio-one, Kremsmünster, Austria).

    Generated:

    Article Title: Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen.
    Article Snippet: 0003-2697/$ see front matter 2013 Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/j.ab.2013.04.016 ⇑ Corresponding author.. Fax: +1 617 551 7919.. E-mail address: michael.bembenek@mpi.com (M.E.

    Recombinant:

    Article Title: Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen.
    Article Snippet: 0003-2697/$ see front matter 2013 Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/j.ab.2013.04.016 ⇑ Corresponding author.. Fax: +1 617 551 7919.. E-mail address: michael.bembenek@mpi.com (M.E.

    Protease Inhibitor:

    Article Title: Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen.
    Article Snippet: 0003-2697/$ see front matter 2013 Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/j.ab.2013.04.016 ⇑ Corresponding author.. Fax: +1 617 551 7919.. E-mail address: michael.bembenek@mpi.com (M.E.



    Similar Products

    90
    Thermo Fisher alphalisa® lysis buffer concentrate (5)
    Alphalisa® Lysis Buffer Concentrate (5), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alphalisa+buffer/alphalisa++lysis+buffer+concentrate++5+/us12351591-1388-14-24
    Average 90 stars, based on 1 article reviews
    alphalisa® lysis buffer concentrate (5) - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    91
    Revvity 5x alphalisa lysis buffer
    5x Alphalisa Lysis Buffer, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alphalisa+buffer/AlphaLISA+Lysis+Buffer%2C+5X/us11827642-845-6-10
    Average 91 stars, based on 1 article reviews
    5x alphalisa lysis buffer - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    91
    Revvity alphalisa buffer
    (A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
    Alphalisa Buffer, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alphalisa+buffer/10X+AlphaLISA+Binding+Assay+Buffer/pmc10491024-223-10-34
    Average 91 stars, based on 1 article reviews
    alphalisa buffer - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    91
    Revvity ripa lysis buffer
    (A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
    Ripa Lysis Buffer, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alphalisa+buffer/AlphaLISA+Lysis+Buffer%2C+5X/pmc10388529-120-2-5
    Average 91 stars, based on 1 article reviews
    ripa lysis buffer - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    91
    Revvity alphalisa lysis buffer
    (A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
    Alphalisa Lysis Buffer, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alphalisa+buffer/AlphaLISA+Lysis+Buffer%2C+5X/pmc10373114-47-32-35
    Average 91 stars, based on 1 article reviews
    alphalisa lysis buffer - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    91
    Revvity alphalisa immunoassay
    (A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
    Alphalisa Immunoassay, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alphalisa+buffer/AlphaLISA+Bovine+Immunoassay+Buffer/pmc10400289-82-10-12
    Average 91 stars, based on 1 article reviews
    alphalisa immunoassay - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    91
    Revvity 1x alphalisa buffer
    Smaller antibody formats more effectively penetrate the human corneal epithelium and remain functional following penetration. ( A ) Schematic depiction of the 3D human epithelial corneal tissue model grown in cell culture inserts. IF8-Fc, db V2D7, and scFv V2D7 were applied topically on the corneal tissue layer at a concentration of 500 nM and left to penetrate for 6 h. ( B ) H&E-stained cross-section of 3D human corneal epithelial tissue model (upper image) and human corneal tissue (bottom image). AL: apical layer; WC: wing cells; BL: basal layer; M: microporous membrane; S: stroma ( C ) Percentage (%) of the antibody compared to the initial input or ( D ) antibody concentration (nM) that crossed the corneal epithelial layer after 6 h determined with an <t>AlphaLISA</t> assay. Representative plots of one out of two experiments performed. Mean of n = 3–8 replicates. ( E ) Human corneal epithelial cells express ALCAM, as assessed by flow cytometry (n = 1). ( F ) Transepithelial electrical resistance (TEER) of the 3D corneal tissue model measured after the penetration assay. Representative plot of one out of two experiments performed. Mean of n = 4 replicates. ( G ) Schematic depiction of the dendritic cell (DC) transmigration assay performed in transwells containing a lymphatic endothelial cell (LEC) monolayer. The medium from the penetration assay containing mAbs that crossed the corneal epithelial layer was applied to the top of the transwell to assess its ability to block DC transmigration towards the chemokine CCL21. ( H ) DC transmigration performed in the presence of the medium collected from the corneal tissue penetration assays (see A – D ) with scFv, db and IF8-Fc (one technical replicate out of two shown) or negative control PBS (n = four transwells per condition). IF8-Fc at 1 nM was used as a positive control, and PBS was used as the negative control (control). Representative plot of one out of two experiments. Statistics: One-way ANOVA, Holm–Sidak multiple comparison test ( C , D ) or Dunnett’s multiple comparison test ( H ).
    1x Alphalisa Buffer, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/alphalisa+buffer/Immunoassay+buffer%2C+10X/pmc10385607-181-11-15
    Average 91 stars, based on 1 article reviews
    1x alphalisa buffer - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    Image Search Results


    (A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) AlphaLISA screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .

    Journal: Cell reports

    Article Title: HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide

    doi: 10.1016/j.celrep.2023.112755

    Figure Lengend Snippet: (A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) AlphaLISA screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .

    Article Snippet: RATP-Ig supernatants from glycan-base BG505-positive B cells were diluted into AlphaLISA buffer (PBS +0.05% Tween 20 + 0.5 mg/mL BSA), and 5 μL of each were transferred to an OptiPlate-384 assay plate (white opaque, PerkinElmer, Waltham, MA).

    Techniques: FACS, Binding Assay, Purification, Negative Control, Neutralization

    Smaller antibody formats more effectively penetrate the human corneal epithelium and remain functional following penetration. ( A ) Schematic depiction of the 3D human epithelial corneal tissue model grown in cell culture inserts. IF8-Fc, db V2D7, and scFv V2D7 were applied topically on the corneal tissue layer at a concentration of 500 nM and left to penetrate for 6 h. ( B ) H&E-stained cross-section of 3D human corneal epithelial tissue model (upper image) and human corneal tissue (bottom image). AL: apical layer; WC: wing cells; BL: basal layer; M: microporous membrane; S: stroma ( C ) Percentage (%) of the antibody compared to the initial input or ( D ) antibody concentration (nM) that crossed the corneal epithelial layer after 6 h determined with an AlphaLISA assay. Representative plots of one out of two experiments performed. Mean of n = 3–8 replicates. ( E ) Human corneal epithelial cells express ALCAM, as assessed by flow cytometry (n = 1). ( F ) Transepithelial electrical resistance (TEER) of the 3D corneal tissue model measured after the penetration assay. Representative plot of one out of two experiments performed. Mean of n = 4 replicates. ( G ) Schematic depiction of the dendritic cell (DC) transmigration assay performed in transwells containing a lymphatic endothelial cell (LEC) monolayer. The medium from the penetration assay containing mAbs that crossed the corneal epithelial layer was applied to the top of the transwell to assess its ability to block DC transmigration towards the chemokine CCL21. ( H ) DC transmigration performed in the presence of the medium collected from the corneal tissue penetration assays (see A – D ) with scFv, db and IF8-Fc (one technical replicate out of two shown) or negative control PBS (n = four transwells per condition). IF8-Fc at 1 nM was used as a positive control, and PBS was used as the negative control (control). Representative plot of one out of two experiments. Statistics: One-way ANOVA, Holm–Sidak multiple comparison test ( C , D ) or Dunnett’s multiple comparison test ( H ).

    Journal: Pharmaceutics

    Article Title: Optimization and Characterization of Novel ALCAM-Targeting Antibody Fragments for Transepithelial Delivery

    doi: 10.3390/pharmaceutics15071841

    Figure Lengend Snippet: Smaller antibody formats more effectively penetrate the human corneal epithelium and remain functional following penetration. ( A ) Schematic depiction of the 3D human epithelial corneal tissue model grown in cell culture inserts. IF8-Fc, db V2D7, and scFv V2D7 were applied topically on the corneal tissue layer at a concentration of 500 nM and left to penetrate for 6 h. ( B ) H&E-stained cross-section of 3D human corneal epithelial tissue model (upper image) and human corneal tissue (bottom image). AL: apical layer; WC: wing cells; BL: basal layer; M: microporous membrane; S: stroma ( C ) Percentage (%) of the antibody compared to the initial input or ( D ) antibody concentration (nM) that crossed the corneal epithelial layer after 6 h determined with an AlphaLISA assay. Representative plots of one out of two experiments performed. Mean of n = 3–8 replicates. ( E ) Human corneal epithelial cells express ALCAM, as assessed by flow cytometry (n = 1). ( F ) Transepithelial electrical resistance (TEER) of the 3D corneal tissue model measured after the penetration assay. Representative plot of one out of two experiments performed. Mean of n = 4 replicates. ( G ) Schematic depiction of the dendritic cell (DC) transmigration assay performed in transwells containing a lymphatic endothelial cell (LEC) monolayer. The medium from the penetration assay containing mAbs that crossed the corneal epithelial layer was applied to the top of the transwell to assess its ability to block DC transmigration towards the chemokine CCL21. ( H ) DC transmigration performed in the presence of the medium collected from the corneal tissue penetration assays (see A – D ) with scFv, db and IF8-Fc (one technical replicate out of two shown) or negative control PBS (n = four transwells per condition). IF8-Fc at 1 nM was used as a positive control, and PBS was used as the negative control (control). Representative plot of one out of two experiments. Statistics: One-way ANOVA, Holm–Sidak multiple comparison test ( C , D ) or Dunnett’s multiple comparison test ( H ).

    Article Snippet: In brief, 10 µL of 10 nM hALCAM V1 diluted in 1X AlphaLISA buffer (AL000C, PerkinElmer) was added to wells of a 96-well plate (6002350, PerkinElmer).

    Techniques: Functional Assay, Cell Culture, Concentration Assay, Staining, Flow Cytometry, Transmigration Assay, Blocking Assay, Negative Control, Positive Control